BFC
SPRO icon

Bedel Financial Consulting’s Spero Therapeutics SPRO Stock Holding History

Bedel Financial Consulting’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,837
Closed -$33K – 789
2022
Q1 		$33K Hold
3,837
– – 0.01% 469
2021
Q4 		$61K Hold
3,837
– – 0.02% 361
2021
Q3 		$71K Hold
3,837
– – 0.02% 332
2021
Q2 		$54K Buy
+3,837
New +$53.6K 0.02% 362

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bedel Financial Consulting's SPRO Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Spero Therapeutics (SPRO) in Q2 2022, closing a stake of 3,837 shares — an estimated $33K sold.

Bedel Financial Consulting first reported a position in SPRO in Q2 2021 and held it in 4 quarters. The position peaked at $71K in Q3 2021. 79 funds tracked by Wall St. Rank hold SPRO as of Q2 2022.

  • Bedel Financial Consulting reported no remaining Spero Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 3,837 Spero Therapeutics shares in Q2 2022, an estimated $33K.
  • Bedel Financial Consulting first reported a position in Spero Therapeutics in Q2 2021 and held it in 4 quarters.
  • Bedel Financial Consulting's Spero Therapeutics position peaked at $71K in Q3 2021.
  • 79 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.